CIMP, D29/D33 MRD (0.1%), and survival in the study of NOPHO ALL2008 and validation DCOG ALL-10/ALL-11 cohorts. (A-D) pEFS and (E-H) pOS probabilities in pediatric patients with T-ALL stratified by CIMP and MRD. In the NOPHO cohort, samples were grouped by CIMP (n = 116 CIMP high and n = 76 CIMP low), at D29 MRD (<0.1%, n = 128 and ≥0.1%, n = 101), or CIMP and D29 MRD combined subgroups (CIMP low/D29 MRD ≥ 0.1%, n = 38; CIMP low/D29 MRD < 0.1%, n = 35; CIMP high/D29 MRD ≥ 0.1%, n = 42; and CIMP high/D29 MRD < 0.1%, n = 57). In the validation DCOG cohort, CIMP and D33 MRD were combined (CIMP low/D33 MRD ≥ 0.1%, n = 26; CIMP low/D33 MRD < 0.1%, n = 27; CIMP high/D33 MRD ≥ 0.1%, n = 26; and CIMP high/D33 MRD < 0.1%, n = 58).